Targeted alpha-particle therapy

It employs radioactive substances which undergo alpha decay to treat diseased tissue at close proximity.

[2] As in diagnostic nuclear medicine, appropriate radionuclides can be chemically bound to a targeting biomolecule which carries the combined radiopharmaceutical to a specific treatment point.

[4] The primary advantage of alpha particle (α) emitters over other types of radioactive sources is their very high linear energy transfer (LET) and relative biological effectiveness (RBE).

[9] Treatment of peritoneal carcinomas has promising early results limited by availability of α-emitters compared to β-emitters.

[20][21] Potential methods to solve this problem of delivery exist, such as direct intratumoral injection[22] and anti-angiogenic drugs.